Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:SRPT NASDAQ:STOK NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$5.36-1.2%$5.42$4.41▼$8.69$2.00B0.421.98 million shs781,620 shsSRPTSarepta Therapeutics$17.01-3.1%$20.01$10.41▼$44.14$1.80B0.262.96 million shs3.90 million shsSTOKStoke Therapeutics$29.03-3.5%$33.92$9.09▼$40.22$1.81B1.2716,489 shs736,427 shsSTTKShattuck Labs$5.97-4.6%$6.64$0.71▼$8.33$457.78M1.18620,235 shs608,935 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-6.11%-8.33%-9.54%+15.98%SRPTSarepta Therapeutics0.00%-12.03%-18.56%-1.35%-51.83%STOKStoke Therapeutics0.00%-8.54%-19.29%-5.73%+208.20%STTKShattuck Labs0.00%-8.61%-16.87%+62.18%+469.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$5.36-1.2%$5.42$4.41▼$8.69$2.00B0.421.98 million shs781,620 shsSRPTSarepta Therapeutics$17.01-3.1%$20.01$10.41▼$44.14$1.80B0.262.96 million shs3.90 million shsSTOKStoke Therapeutics$29.03-3.5%$33.92$9.09▼$40.22$1.81B1.2716,489 shs736,427 shsSTTKShattuck Labs$5.97-4.6%$6.64$0.71▼$8.33$457.78M1.18620,235 shs608,935 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-6.11%-8.33%-9.54%+15.98%SRPTSarepta Therapeutics0.00%-12.03%-18.56%-1.35%-51.83%STOKStoke Therapeutics0.00%-8.54%-19.29%-5.73%+208.20%STTKShattuck Labs0.00%-8.61%-16.87%+62.18%+469.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.80Reduce$8.0049.39% UpsideSRPTSarepta Therapeutics 2.11Hold$27.7162.89% UpsideSTOKStoke Therapeutics 2.73Moderate Buy$41.8344.10% UpsideSTTKShattuck Labs 2.67Moderate Buy$13.00117.76% UpsideCurrent Analyst Ratings BreakdownLatest STTK, STOK, BHC, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/11/2026STOKStoke Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/8/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/8/2026STTKShattuck Labs WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $11.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/27/2026STTKShattuck Labs Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight4/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/20/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $18.004/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell4/10/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.19$7.24 per share0.74$1.02 per share5.25SRPTSarepta Therapeutics$2.20B0.82N/AN/A$10.89 per share1.56STOKStoke Therapeutics$184.42M9.80N/AN/A$6.17 per share4.71STTKShattuck Labs$1M457.78N/AN/A$1.30 per share4.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.40N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A7.430.20-2.94%7.56%2.94%8/5/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%N/ASTTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%N/ALatest STTK, STOK, BHC, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/A5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion3/16/2026Q4 2025STOKStoke TherapeuticsN/A-$0.97N/A-$0.97N/A$1.40 million3/5/2026Q4 2025STTKShattuck Labs-$0.12-$0.12N/A-$0.12$0.17 million($1.00) million2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 million2/18/2026Q4 2025BHCBausch Health Cos$1.21$1.08-$0.13-$0.30$2.71 billion$2.78 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97SRPTSarepta Therapeutics0.564.632.62STOKStoke TherapeuticsN/A8.998.99STTKShattuck LabsN/A22.0722.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%SRPTSarepta Therapeutics86.68%STOKStoke TherapeuticsN/ASTTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%SRPTSarepta Therapeutics6.90%STOKStoke Therapeutics9.50%STTKShattuck Labs8.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300373.81 million296.55 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSTOKStoke Therapeutics10062.28 million56.37 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableSTTK, STOK, BHC, and SRPT HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in StockMay 15 at 9:03 AM | insidertrades.comWe're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn RateMay 11, 2026 | finance.yahoo.comShattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comWedbush Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) StockMay 8, 2026 | marketbeat.comShattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | finanznachrichten.deShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comCantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)May 1, 2026 | insidermonkey.comShattuck Labs (STTK) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comShattuck Labs (STTK) price target increased by 24.00% to 12.65April 29, 2026 | msn.comCantor Fitzgerald initiates coverage of Shattuck Labs (STTK) with overweight recommendationApril 28, 2026 | msn.comShattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 28, 2026 | marketbeat.comShattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Cantor FitzgeraldApril 27, 2026 | marketbeat.comHC Wainwright Forecasts Stronger Earnings for Shattuck LabsApril 22, 2026 | marketbeat.comShattuck Labs (NASDAQ:STTK) Hits New 1-Year High - Time to Buy?April 21, 2026 | marketbeat.comShattuck Labs (NASDAQ:STTK) Stock Price Up 6% - What's Next?April 20, 2026 | marketbeat.comShattuck Labs: Surviving In An AI World Is Going To Be ToughMarch 27, 2026 | seekingalpha.comShattuck Labs (STTK) price target increased by 37.93% to 10.20March 27, 2026 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH)March 14, 2026 | theglobeandmail.comShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business ...March 5, 2026 | caledonianrecord.comCShattuck Labs Advances SL-325 Clinical Trials, Reports Financial Results for Q4 and Full Year 2025March 5, 2026 | quiverquant.comQShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business HighlightsMarch 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTTK, STOK, BHC, and SRPT Company DescriptionsBausch Health Cos NYSE:BHC$5.36 -0.07 (-1.20%) Closing price 03:59 PM EasternExtended Trading$5.35 -0.01 (-0.09%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Sarepta Therapeutics NASDAQ:SRPT$17.01 -0.54 (-3.08%) Closing price 04:00 PM EasternExtended Trading$17.06 +0.05 (+0.29%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Stoke Therapeutics NASDAQ:STOK$29.03 -1.05 (-3.49%) Closing price 04:00 PM EasternExtended Trading$29.05 +0.02 (+0.07%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Shattuck Labs NASDAQ:STTK$5.97 -0.29 (-4.63%) Closing price 04:00 PM EasternExtended Trading$5.98 +0.02 (+0.25%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
